Skip to main content

Cardiac Rehabilitation Use Low in Distressed Communities

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 30, 2023.

By Lori Solomon HealthDay Reporter

WEDNESDAY, Nov. 29, 2023 -- Although community-level distress is associated with lower cardiac rehabilitation (CR) participation, the clinical benefits are universal across all communities, according to a study published in the November issue of Circulation: Cardiovascular Quality and Outcomes.

Michael P. Thompson, Ph.D., from Michigan Medicine in Ann Arbor, and colleagues evaluated the relationship between community-level distress and CR participation, access to CR facilities, and clinical outcomes. The analysis included 414,730 Medicare beneficiaries undergoing inpatient coronary revascularization between July 2016 and December 2018.

The researchers found that any CR use was lower for beneficiaries in distressed versus prosperous communities (26.0 versus 46.1 percent), which remained significant after multivariable adjustment (odds ratio, 0.41). One-quarter of beneficiaries (23.7 percent) had a CR facility within their ZIP code, which increased from 16.3 percent in prosperous communities to 26.6 percent in distressed communities. There was an association observed between any CR use and absolute reductions in mortality (−6.8 percent), all-cause hospitalization (−5.9 percent), and acute myocardial infarction hospitalization (−1.3 percent), which were similar across Distressed Community Index quintiles.

"Addressing barriers to participation in cardiac rehabilitation in distressed communities may improve outcomes for these patients and reduce longstanding disparities in such outcomes," Thompson said in a statement.

One author disclosed ties to Medtronic, Abbott, FineHeart, and CH Biomedical.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM

FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...

DNA Methylation-Based Epigenetic Age Mediates Link Between LE8 Score, CVD

WEDNESDAY, May 29, 2024 -- The associations between Life's Essential 8 (LE8) and cardiovascular health are mediated by DNA methylation-based epigenetic age, according to a study...

Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease

TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.